Extensively-drug resistant Acinetobacter baumannii bacteremia in neonates: effective treatment with the combination of colistin and ampicillin/sulbactam

J Chemother. 2020 Apr;32(2):103-106. doi: 10.1080/1120009X.2020.1716478. Epub 2020 Jan 29.

Abstract

Acinetobacter baumannii has evolved as a major pathogen of outbreaks in the healthcare setting with increased morbidity and mortality. In neonates, treatment can be quite challenging due to the resistance profile of A. baumannii as well as limited data on pharmakokinetics and pharmakodynamics of antibiotics in this age group. We present an outbreak of eight cases of extensively-drug resistant (XDR) A. baumannii bacteremias successfully managed with the combination of colistin with high dose ampicillin/sulbactam.

Keywords: Acinetobacter baumannii; Extensively-drug resistant; ampicillin/sulbactam; colistin; neonates.

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter baumannii
  • Ampicillin / administration & dosage
  • Ampicillin / therapeutic use
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy*
  • Cross Infection / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Resistance, Multiple, Bacterial
  • Drug Therapy, Combination
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Microbial Sensitivity Tests
  • Retrospective Studies
  • Sulbactam / administration & dosage
  • Sulbactam / therapeutic use

Substances

  • Anti-Bacterial Agents
  • sultamicillin
  • Ampicillin
  • Sulbactam